Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02867007 · ClinicalTrials.gov registry record · Phase 1
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02867007 is a Phase 1 study that has completed, run by Kyowa Kirin. The registered enrollment target is 36 participants.
The verdict
NCT02867007, a Phase 1 study, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety, tolerability, and determine the maximum tolerated dose (MTD) or the highest protocol-defined dose, in the absence of exceeding the MTD, of KHK2455 administered orally in combination with mogamulizumab to subjects with locally advanced or metastatic solid tumors.
Interventions
- DRUG Mogamulizumab
- DRUG KHK2455
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-08 |
| Est. Completion | 2019-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02867007
The ClinicalTrials.gov registry entry for NCT02867007 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mogamulizumab is the first listed.
NCT02867007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02867007 about?
NCT02867007 is a clinical study titled "KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors". The purpose of this study is to characterize the safety, tolerability, and determine the maximum tolerated dose (MTD) or the highest protocol-defined dose, in the absence of exceeding the MTD, of KHK2455 administered orally in combination with mogamulizumab to subjects with locally advanced or metas...
What is the current status of trial NCT02867007?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-08. Estimated completion is 2019-12-15.
What interventions are being tested in trial NCT02867007?
The interventions under investigation include: Mogamulizumab (DRUG), KHK2455 (DRUG).
Who is sponsoring clinical trial NCT02867007?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.